PUBLICATIONS

Description:

We encourage our investigators to conduct research and publish their own studies or co-author publications in collaboration with other experts in the field of Health Research.

    List of Publications:

  1. Acceptability of 100-mg moxifloxacin in children with rifampicin-resistant TB in three high-burden countries
    2.
  2. Pharmaceutical cost dynamics for the treatment of rifampicin-resistant tuberculosis in children and adolescents in South Africa, India, and the Philippines. PLOS ONE. 19. 10.1371/journal.pone.0305930.
    3.
  3. Delamanid Added to an Optimized Background Regimen in Children with Multidrug-Resistant Tuberculosis: Results of a Phase I/II Clinical Trial. Antimicrob Agents Chemother. 2022 May 17;66(5):e0214421. doi: 10.1128/aac.02144-21. Epub 2022 Apr 11. PMID: 35404075; PMCID: PMC9112969
    4.
  4. Bedaquiline for multidrug-resistant TB in paediatric patients. Int J Tuberc Lung Dis. 2021 Sep 1;25(9):716-724. doi: 10.5588/ijtld.21.0022. PMID: 34802493; PMCID: PMC8412106
    5.
  5. Tucker EW, et al. Delamanid Central Nervous System Pharmacokinetics in Tuberculous Meningitis in Rabbits and Humans. Antimicrob Agents Chemother. 2019;63:e00913-19. PMID: 31383662; PMCID: PMC6761520.
    6.
  6. Kawasaki M, et al. Lipoarabinomannan in sputum to detect bacterial load and treatment response in patients with pulmonary tuberculosis. PLoS Med. 2019;16(4):e1002780. doi: 10.1371/journal.pmed.1002780.
    7.
  7. Estimating the future burden of multidrug-resistant and extensively drug-resistant tuberculosis in India, the Philippines, Russia, and South Africa. Lancet Infect Dis. 2017;17:707-715. PMID: 28499828
    8.
  8. Multidrug-resistant tuberculosis treatment failure detection depends on monitoring interval and microbiological method. Eur Respir J. 2016;48:1160-1170. PMID: 27587552
    9.
  9. Predicting differential rifamycin resistance in clinical Mycobacterium tuberculosis isolates by specific rpoB mutations. Int J Tuberc Lung Dis. 2015;19:1222-6. doi: 10.5588/ijtld.14.0936.
    10.
  10. Novel katG mutations causing isoniazid resistance in clinical M. tuberculosis isolates. Emerg Microbes Infect. 2015;4:e42. doi: 10.1038/emi.2015.42.
    11.
  11. Evaluation of pyrosequencing for detecting extensively drug-resistant Mycobacterium tuberculosis among clinical isolates from four high-burden countries. Antimicrob Agents Chemother. 2015;59:414-20. doi: 10.1128/AAC.03614-14.
    12.
  12. Extensive drug resistance acquired during treatment of multidrug-resistant tuberculosis. Clin Infect Dis. 2014;59:1049-63. PMID: 25057101; PMCID: PMC4184341.
    13.
  13. Predicting extensively drug-resistant Mycobacterium tuberculosis phenotypes with genetic mutations. J Clin Microbiol. 2014;52:781-9. PMCID: PMC3957771.
    14.
  14. Weight gain and response to treatment for multidrug-resistant tuberculosis. Am J Trop Med Hyg. 2013;89:943-9. PMCID: PMC3820341
    15.
  15. Patterns of treatment interruption among patients with multidrug-resistant TB (MDR-TB). PLoS One. 2013;8:e70064. doi: 10.1371/journal.pone.0070064. PMCID: PMC3726487.
    16.
  16. Prevalence of and risk factors for resistance to second-line drugs in people with multidrug-resistant tuberculosis. Lancet. 2012;380:1406-17. PMID: 22938757.
    17.
  17. Screening Outcomes from Patients with Suspected Multidrug-resistant TB – Lessons Learned in the Philippines. Int J Tuberc Lung Dis. 2012 Oct;16(10):1326-30. doi: 10.5588/ijtld.12.0038
    18.
  18. Impact of patient and program factors on default during treatment of multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2012;16:955-960. PMID 21756517
    19.
  19. Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med. 2012;366:2151-60. PMID: 22670901.
    20.
  20. Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test. Lancet. 2011;377:1495-505. PMID: 21507477; PMCID: PMC3085933.
    21.
  21. The rapid diagnosis of tuberculosis with Xpert MTB-RIF assay in high burden countries: a cost-effectiveness analysis. PLoS Med. 2011;8(11): e1001120. doi:10.1371/journal.pmed.1001120
    22.
  22. Thrombocytopenia associated with dengue hemorrhagic fever responds to intravenous anti-D (Rh(0)-D) immune globulin. Am J Trop Med Hyg. 2007;76(4):737-42. PMID: 17426181.
    23.